By incubation of tebufenpyrad with rat liver
homogenate, tebufenpyrad undergoes
biotransformation to yield the major metabolites N-(4-
tert-butylbenzyl)-4-chloro-3-(1-hydroxyethyl)-1-
methylpyrazole-5-carboxamide via hydroxylation of the
w-1-carbon of the ethyl group and N-[4-(1-carboxy-1-
methylethyl)benzyl]-4-chloro-3-ethyl-1-methylpyrazole-
5-carboxamide via oxidation of the methyl group in the
tert-butyl moiety to the carboxylic acid derivatives.
When the rat is orally dosed tebufenpyrad, the major
metabolism pathway is via both hydroxylation and
oxidation reactions to yield N-[4-(1-carboxy-1-
methylethyl)benzyl]-4-chloro-3-(1-hydroxyethyl)-1-
methylpyrazole-5-carboxamide which is mainly
excreted in the urine.